GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved a 200 mg/mL autoinjector of Benlysta, a B-lymphocyte stimulator-specific inhibiting monoclonal antibody, for subcutaneous injection in patients five years of age and older with active lupus nephritis who are receiving standard therapy. “With this approval, GSK is expanding choices for belimumab treatment, offering pediatric lupus nephritis patients and caregivers a first-of-its-kind subcutaneous option that can be administered at home. The 200 mg/mL autoinjector was approved for pediatric patients with active systemic lupus erythematosus in 2024,” the company stated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces EMA has accepted for review the MAA for use of linerixibat
- GSK Pharma put volume heavy and directionally bearish
- GSK announces Japan’s MHLW accepts application to expand use of Arexvy
- Kennedy considers review of aluminum in vaccines, Bloomberg says
- Trump administration weighs crackdown on pharma ads, Bloomberg says